TriMixDC-MEL as Adjuvant Treatment for Stage III/IV Disease-Free Melanoma Patients Following the Resection of Macrometastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Randomized Controlled Phase II Clinical Trial on mRNA Electroporated Autologous Monocyte-Derived Dendritic Cells (TriMixDC-MEL) as Adjuvant Treatment for Stage III/IV Melanoma Patients Who Are Disease-Free Following the Resection of Macrometastases
Cancer Immunol. Immunother. 2020 Jun 26;[EPub Ahead of Print], Y Jansen, V Kruse, J Corthals, K Schats, PJ van Dam, T Seremet, C Heirman, L Brochez, M Kockx, K Thielemans, B NeynsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.